MannKind | MNKD - Cost Of Sales

Stock Price
5.79
Daily Change
0.28 4.99%
Monthly
-1.11%
Yearly
2.75%
Q1 Forecast
5.60

MannKind reported $20.2M in Cost of Sales for its fiscal quarter ending in September of 2025.





Cost Of Sales Change Date
Adma Biologics USD 58.64M 3.88M Sep/2025
Dynavax Technologies USD 14.4M 368K Sep/2025
Eli Lilly USD 3.37B 363.7M Dec/2025
Halozyme Therapeutics USD 73M 8.88M Sep/2025
Insmed USD 30.9M 1.56M Sep/2025
MacroGenics USD 44.3M 5.4M Sep/2025
MannKind USD 20.2M 365K Sep/2025
Merck USD 3.32B 531M Dec/2025
Novo Nordisk DKK 1.95B 10.94B Jun/2025
Pfizer USD 6.29B 2.12B Dec/2025
Sanofi EUR 4.29B 421M Dec/2025
Xencor USD 61.66M 50.95M Jun/2025